Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393690 · ClinicalTrials.gov registry record · Phase 2
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02393690 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 60 participants.
The verdict
NCT02393690, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned (recurrent) or has spread from where it started to other places in the body (metastatic). Many thyroid cancers absorb iodine. Due to this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.
Interventions
- DRUG Selumetinib
- OTHER Placebo Administration
- RADIATION Iodine I-131
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-05-04 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393690
The ClinicalTrials.gov registry entry for NCT02393690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Selumetinib is the first listed.
NCT02393690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02393690 about?
NCT02393690 is a clinical study titled "Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer". This phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned (recurrent) or has spread from where it started to other places in the body (metastatic). Many thyroid cancers absorb iodine. Due to this, doctors often give...
What is the current status of trial NCT02393690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2015-05-04. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT02393690?
The interventions under investigation include: Selumetinib (DRUG), Placebo Administration (OTHER), Iodine I-131 (RADIATION).
Who is sponsoring clinical trial NCT02393690?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.